Clinical Trial Update: Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating silodosin for severe benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Rapaflo (silodosin)

Snippet

Sponsor: JW Pharmaceutical | Conditions: Benign Prostatic Hyperplasia | Phase 4 | Status: COMPLETED